How p53 mutations drive immunotherapy resistance—and a path to overcome it. Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from researchers at the Hackensack Meridian Center for Discovery and Innovation (CDI) identifies a previously unrecognized mechanism by which mutations in the p53 gene can limit the effectiveness of immunotherapy—while also revealing a potential strategy to overcome this resistance.
- Ponto de atenção: mutations.
- Ponto de atenção: drive.
- Ponto de atenção: immunotherapy.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/14a92889-913d-4e5c-b163-f5732ff828e5.jpeg)
